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Introduction
The risk of herb-drug interaction (HDI) is increasingly recognized as a public health problem often accompanied by life-threatening adverse drug events, prolonged hospitalization and loss of life [1] . With a rise in global burden of noncommunicable diseases [2] [3] [4] [5] , pain syndromes, anxiety, depression and aging [6, 7] , co-usage of prescribed medications and herbal products will persistently be a potential health problem in both developed and developing nations. For instance, cases of acute rejection episodes have been reported in heart, renal or liver transplant patients stabilized on immunosuppressives including cyclosporine and tacrolimus due to concomitant intake of St John's wort (SJW) known to induce drug metabolizing enzymes [8, 9] . In two case reports, patients with a history of generalized anxiety disorder and mild traumatic brain injury experienced serotonin syndrome and hypomania after addition of SJW or Ginkgo biloba to either a buspirone or fluoxetine regimen [10, 11] . Patients' deliberate refusal to disclose their use of herbal medicines to clinicians have led to underreporting of clinically relevant HDI cases. In addition, underestimation of the consequences of HDI due to lack of a standardized probability scoring system has contributed to wrong classification of the causality of adverse drug reactions (ADRs). Different experimental models have been used to understand the mechanism of such interactions [12] [13] [14] [15] .
In most instances, in vitro and animal studies are conducted to evaluate the effect of herbal extracts and phytochemical constituents on pharmacokinetic and pharmacodynamic properties of probe drugs [16] [17] [18] [19] [20] [21] [22] . However, preclinical investigations often do not correlate with findings in human subjects [23] [24] [25] [26] [27] . Clinical studies in patients adopting a population pharmacokinetic approach is considered as the gold standard to determine the clinical consequences of potential interaction of herbal medicines with prescribed medications [28] . Nevertheless, pharmacokinetic interaction studies are often conducted in healthy subjects [29, 30] . Incidences of ADRs are rarely reported in these types of studies due to limited number of co-administered drugs, small sample size, lack of an appropriate placebo arm and the recruitment of healthy young subjects. Only a few cases recorded HDI-linked ADRs and the causality of adverse effect was assessed using an appropriate classification tool [31, 32] .
Few studies have adapted the Naranjo tool to classify the severity of HDI [33, 34] . The Naranjo tool was designed to evaluate ADRs due to a single agent, and it is thus less useful for the categorization of HDI linked ADRs [35] . Fugh-Berman and Ernst developed a 10-point scoring system to assess the reliability scale of HDI [36] . Later, Horn and colleagues proposed a specific tool for causality assessment of drug-drug interactions by adopting the Naranjo scale as a guide. The Horn's drug interaction probability scale (DIPS) consists of 10 questions each with three response options to which a score is assigned [37] . In 1985, the French pharmaceutical company Roussel Uclaf organized a consensus meeting for experts in hepatology to define terminologies used in drug induced liver injuries (DILI) assessment and qualitative criteria based on the French causality assessment method (CAM). The meeting outcomes included additional criteria and assigned weight to each criterion leading to the Roussel Uclaf Causality Assessment Method (RUCAM). RUCAM is regarded as a wellestablished tool for qualitative assessment of causality in cases of suspected herb-induced liver injury (HILI) and DILI [38] [39] [40] . Nevertheless, only a few HDI studies have applied the Horn's DIPS and RUCAM scores to ascertain the causal relationship of ADRs. In addition, for studies where one or both classification systems were used, the mechanism of HDI was either unclear or not reported. Stockley's herbal medicine interaction companion contains arrays of herbal medicines with documented literature of interaction studies conducted in vitro, in animal models and healthy subjects [41] . Observational and survey control studies have adopted this companion to flag herbal medicines with potential to cause adverse effect due to interaction with prescribed medications. Such information could be useful in educating both clinicians and patients about the consequences of consuming herbal medicines with prescribed medications based on established reports. This review, therefore, aims to conduct causality assessment on HDI in clinical trials, case-controls studies, and case reports in in/out-patients from January 2001 to August 2017 using Horn's DIPS for general HDI and RUCAM for HILI specific injuries, respectively. In addition, the mechanism of HDI was evaluated by using Stockley's herbal medicines interaction companion.
Methods
Databases of PubMed, the Cochrane Library, Medline and Scopus were searched from January 2001 to August 2017. A combination of the following keywords were used for title, abstract and keywords fields: herbal drugs, herbal supplements, phytochemicals, drug interactions, herb-drug interactions, side effect and adverse-effects. Preliminary assessment was conducted on abstracts retrieved from the databases to identify publications that met the pre-specified criteria. Articles describing randomized or nonrandomized clinical studies, case-control and case reports in both inand out-patients where conventional medications and herbal medicines were co-administered met the inclusion criteria. The review excluded all HDI studies conducted in healthy subjects, in vitro and in vivo models and other sources of natural products. Reference lists from eligible publications were another source for articles included in this review. Full text articles of abstracts meeting the eligibility criteria were extracted, validated and summarized (Table 1) . Two independent reviewers (C.A. and M.M.) conducted causality assessment on validated data using the Horn's DIPS for general ADRs or RUCAM for HILI. The Stockley's herbal medicine interaction companion was consulted in cases where the mechanism of interaction was not reported.
The results of this review are divided into two parts: 1) characteristics of studies, and 2) tabularized description of studies, probability score and mechanism of interactions.
Results
The initial electronic database search identified 5113 articles, of which 1963 were screened after removal of duplications. In total 5035 publications were excluded based on titles and abstracts. On application of the review inclusion criteria to the 78 full-text papers, a further 24 articles were excluded. Five additional papers were discarded because full text of two studies were not available, two papers in German and one paper in Turkish could not be translated into English. Thus, 49 full text articles consisting of 47 case reports publications and two observational studies were included in this review. One publication presented three different reports and hence, 49 case reports were reviewed. The majority of the case reports described patients between 51-69 years (n = 12, 24.49%) and older than 70 years (n = 11, 22.45%), respectively. Fifteen of the patients (30.60%) had a history of cardiovascular conditions such as hypertension, dyslipidaemia, myocardial infarction, atrial fibrillation and cardiomyopathy. Thirteen patients (86.67%) with a history of cardiovascular conditions were on warfarin treatment. Eleven cases (22.45%) were cancer patients of whom the majority were on alkylating agents (busulfan, temozolomide and trabectedin) and/or kinase inhibitors (imatinib and gefitinib). There were eight case reports of patients with renal transplant (16.33%) of which five patients (62.5%) received cyclosporine as immunosuppressive agent. Three HIV positive patients received a protease inhibitor (lopinavir), an integrase inhibitor (raltegravir) or a non-nucleoside reverse transcriptase inhibitor (efavirenz). There were eight patients (16.33%) with central nervous system diseases such as depression, schizophrenia, anxiety disorders and seizures. The patients with central nervous system disorders received anticonvulsants (lamotrigine and phenytoin), atypical antipsychotics (clozapine), a selective serotonin reuptake inhibitor (sertraline) or a norepinephrine reuptake inhibitor (venlafaxine). Concomitant intake of (7) aspirin (7) clopidogrel (7) rebamipide (5) Herbs interact with prescribed medicines SJW and Panax ginseng were recorded in patients treated with warfarin, cyclosporine or kinase inhibitors (gefitinib and imatinib). HDI cases reported to be probable and highly probable were 25 (51.02%) and four (8.16%), respectively. Eighteen cases (36.73%) were classified as possible whilst two cases (4.08%) were identified to be doubtful. The predominant ADRs were elevated liver enzymes, INR, GIT disturbances and rhabdomyolysis. The detailed descriptions and causality scales of the 49 cases included in this review are presented in Table 2 .
The majority of patients in the two observational studies were aged between 51-61 years. Female patients (532 patients, 69.0%) constituted the majority. Most of the patients had a history of metabolic, cardiovascular, endocrine or haemato-oncological complications (Table 1 ). In the study by Jeong et al., six cases of ADRs were reported [31] . Four ADRs were reported in patients with a history of cerebral infarction taking herbal concoctions with NSAIDs (aspirin and diclofenac), P2Y12 inhibitor (clopidogrel) and analgesic (paracetamol) experiencing probable HDI (Table 3) . Levy et al., reported nine cases of ADRs as a consequences of herbal medicine intake [32] . The majority of the cases in this study were due to interaction between warfarin and sage or flaxseed (Table 3) .
Discussion
Concomitant intake of herbal medicines and prescribed medications is a common practice, especially in patients with hypertension, diabetes, cancer, seizures and depression. This is problematic particularly for drugs exhibiting a narrow therapeutic index. Incidences of underreporting and nonstandardized causality estimation of HDI in patients have resulted in life-threatening ADRs, hospitalization and fatality in some cases [87] [88] [89] . Intensification of monitoring and critical appraisal procedures to identify the severity of ADRs linked to concomitant consumption of herbs and prescribed medicines is critical in averting untoward occurrences.
The WHO Collaborating Centre for International Drug Monitoring-Uppsala Monitoring Centre (WHO-UMC) has the mandate to co-ordinate global ADRs data and search this data to identify signals of new ADRs to notify the pharmacovigilance centres of member countries and other organizations concerned with drug safety. In a study conducted by WHO-UMC the majority of HDI-linked ADRs reported were from developed countries, including USA and Europe with South Africa as the only contributory developing country [90] and this re-affirms the concern of underreporting of HDIs in developing countries. Adverse reactions related to HDIs have been documented in observational studies and case reports [70, 71, 83, 84, 91] . Nonetheless, few review studies have been conducted to estimate the severity of the ADRs due to HDI in patients. Hence, this review adapted the DIPS and RUCAM scores to estimate the severity of ADRs, whilst the Stockley's herbal medicines interaction companion was consulted in assessing the mechanism of interactions.
The majority of cases recorded in this study showed that patients taking warfarin and/or statins (atorvastatin, simvastatin and rosuvastatin) for the management of cardiovascular complications reported clinically significant interactions after combination with herbal products including sage, flaxseed, SJW, cranberry, goji juice, green tea and chamomile. Warfarin is a racemic mixture of R and S stereoisomers with S-warfarin being a 3-5 times more potent inhibitor of the vitamin K epoxide reductase complex than the R isomer. Warfarin is used for the management of atrial fibrillation and heart valve replacement. Metabolism of S-warfarin is predominantly mediated by CYP2C9. Herbal medicines altering the activity of CYP2C9 may cause under-anticoagulation or bleeding episodes. Potential interaction of warfarin and active constituents of sage, flaxseed, goji juice, cranberry and chamomile led to ADRs such as ecchymosis, epistaxis, haematuria, hemiplegia and elevated INR [33, 63, 74, 76, 85] . The active constituents of SJW namely hyperforin, flavonols, flavonol glycosides, biflavones, napthodianthrones, acylphloroglucinols and phenylpropranes are known to reduce plasma concentration of warfarin via induction of CYP3A4 and CYP2C9. However, one case study reported SJW to cause sudden upper GIT bleeding in a sensitive patient [61] . This interaction might have been caused by active constituents of SJW potentiating the clotting effect of warfarin. In addition, the Chinese herbal product Sheg Mai-yin is used to improve peripheral circulation due to its effect on oxidative damage in heart, brain and other tissues. Sheg Mai-yin contains red ginseng, liriope and Schisandra chinesis. A case of intracranial haematoma has been reported in a patient with a history of aortic valve and mitral valve replacement receiving warfarin and Sheg Mai-yin [63] . Red ginseng enhances the production of interleukin-1β, which increases the production of tissue plasminogen activators responsible for suppression of thrombin formation during blood coagulation and fibrinolysis processes [92] . Furthermore, the saponin-related active constituents of red ginseng, namely ginsenosides Rg1 and Rg5, downregulate plasminogen inhibitor 1, tissue factor pathway inhibitor, coagulation factors XIII, A1 and coagulation factor II (thrombin) receptor (FR2), which may lead to increase INR [93] .
Besides anticoagulants, patients with cardiovascular complications (coronary artery disease) often take statins, including atorvastatin, rosuvastatin, simvastatin and others to lower low-density lipoprotein and total cholesterol levels. However, many patients on statins complain of muscle pain, which affects quality of life and adherence to treatment. Statin-induced muscle intolerance could be elicited by its co-usage with herbal supplements and other prescribed medications. For example, a patient receiving amlodipine (10 mg day -1 ) and simvastatin (10 mg day -1 ) complained of intense leg muscle cramps and pain after ingestion of green tea [73] . This was attributed to a 2-fold increase plasma levels of simvastatin lactone due to inhibitory effect of green tea on CYP3A4 [94, 95] . However, further studies need to be conducted to ascertain other potential mechanisms for statin intolerance due to green tea intake.
In organ transplant patients, tacrolimus and cyclosporine A are principal immunosuppressive agents commonly administered to protect and reduce episodes of organ rejection. Both drugs have a narrow therapeutic index and are metabolized primarily by CYP3A4/5. Herbal medicines that alter the activities of CYP3A4 are likely to affect the protective effect of tacrolimus and cyclosporine in transplant patients.
Cases of treatment failure or toxicity have been reported in patients consuming tacrolimus, azathioprine and cyclosporine with herbal preparations such as turmeric or chamomile tea [43, 50, 79, 82] . The active phytoconstituents of the herbal medicines inhibit CYP3A4 and P-glycoprotein to reduce elimination of the immunosuppressive agents [96] [97] [98] [99] [100] . Tacrolimus and cyclosporine bind to immunophilins to block calcineurin's mediated T-lymphocyte activation. In general, increased plasma levels of calcineurins have been reported to trigger calcineurin-induced vasoconstriction and release of endothelin-1 (a potent vasoconstrictor), decrease production of nitric oxide and increase expression of transforming growth factor β1 in renal transplantation patients [101] . Thus, the active ingredients of turmeric and chamomile induced nephrotoxicity in patients taking tacrolimus and/or cyclosporine via CYP3A4 inhibition. For probe drugs such as azathioprine, metabolic transformation of parent compound to the active moiety 6-mercaptopurine by glutathione S transferase (GST) and subsequent inactivation to 6-methylmercaptopurine by thiopurine methyltransferase (TPMT) is necessary [102] . Herbal medicines capable of altering the activity of GST and/or TPMT could potentially induce clinically significant ADRs.
Other immunocompromised patients, including those with HIV infections, often take herbs for various reasons, and as immune boosters. A number of antiretroviral medications including protease inhibitors (lopinavir and ritonavir) and non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) with narrow therapeutic indices and elimination via hepatic metabolism are susceptible to HDI. HIV patients experienced signs of toxicity and detectable levels of viral load while taking raltegravir plus lopinavir/ritonavir [58] or efavirenz [59] with ginseng and G. biloba, respectively. The mechanism of ginseng-raltegravir interaction is unknown, as several conflicting outcomes have been reported on the influence of various active ingredients of ginseng on CYP450 enzymes [103] [104] [105] . However, one study reported ginseng-mediated hepatotoxicity in a chronic myeloid leukaemia patient on imatinib due to inhibition of CYP3A4 [34] . The inhibitory effect of ginseng on CYP3A4 was thus probably accountable for the observed adverse effect of raltegravir. For G. biloba, a unique active ingredient, bilobalide, has been demonstrated to induce CYP2B6 mRNA in animal models, although such a result was irreproducible in human subjects [106, 107] . In a patient taking efavirenz and ginkgo, it is speculated that a breakthrough in viral load occurred because of a decrease in plasma levels of EFV as consequence of the inductive effect of active ingredients in G. biloba.
The current review study also recorded a significant number of HDI cases in patients with depression and seizure disorders. Antidepression medications, including valafaxine and sertraline, are eliminated primarily by hepatic metabolism. Patients taking these medications with herbal drugs including QR and Mentat for arthritis and celery root for menopause developed episodes of worsening depression [45, 68] . In addition, cases of seizure induction occurred in a patient taking either phenytoin or valproic acid after consuming G. biloba supplement. In one recorded case, seizure induction led to the demise of a patient while swimming. The autopsy results confirmed a decreased plasma levels of both phenytoin and valproic due to inductive effect of G. biloba on CYP2C19 [80] . Another study in 18 healthy Chinese subjects showed significant reduction in plasma concentration of omeprazole as a probe substrate of CYP2C19 in the presence of G. biloba compared to the controls [108] . Furthermore, Ginkgo contains a potent neurotoxin, 4 0 -0-methoxypyridoxine, which indirectly inhibits glutamate decarboxylase and glycine activities leading to seizure induction [109] . The effect of 4 0 -0-methoxypyridoxine on inhibitory neurotransmitters is predicted as the most likely cause of seizure induction leading to his demise since CYP2C19 would have accounted only for a minor proportion of phenytoin and valproic acid elimination.
Finally, the consumption of herbal medicines is a wellknown practice among cancer patients [110] [111] [112] [113] . Currently, imatinib is the main drug for the treatment of chronic myeloid leukaemia. It is a first-generation inhibitor of bcrabl tyrosine kinase enzyme. Imatinib is primarily metabolized by CYP3A4, and hence, any herbal medicine that alters the activity of CYP3A4, may affect the activity of imatinib. Concomitant intake of imatinib and an energy drink containing P. ginseng led to aberrant liver enzyme levels in a patient [34] . Previous study showed that ginseng increases plasma concentrations of prescribed medications via CYP3A4 inhibition [105] . Thus, the reduced activity of CYP3A4 in the presence of P. ginseng precipitated imatinib-induced hepatotoxicity characterized by late-stage acute lobular hepatitis [105] . Other chemotherapeuticals such as cisplatin, etoposide and trabectedin have been reported to interact with herbal medicines, including Echinacea purpurea [60] and chokeberry juice (Aronia melanocarpa) [53] in patients presenting with different types of cancer. Chokeberry contains concentrated flavonoids -procyanidin B5, cyaniding-3-arabinoside and quercetin -which strongly inhibit CYP3A4 activity in the liver [114] . Thus, reduced activity of CYP3A4 due to chokeberry intake caused trabectedin-induced rhabdomyolysis in this patient [53] . Conversely, echinacea has a mild inhibitory effect on CYP3A4 activity, which is likely to potentiate the myelosuppressive effect of etoposide and could elicit neutropenia and thrombocytopenia in patients.
Conclusion
Patients taking herbal medicines containing G. biloba, P. ginseng, SJW, green tea and others affecting the pharmacokinetic and pharmacodynamic properties of prescribed medications are at risk of experiencing different degrees of HDI. Few case reports of potential HDI have been documented in the literature despite the detrimental consequences of such interactions. In addition, even in cases where HDI were reported in patients, inadequate provision of information hindered the utilization of the data to draw clinically meaningful conclusions. Generally, these challenges could be attributed to a number of reasons including: (i) inability to re-challenge patients with the herbs involved to confirm the causal relationship of the interaction for ethical reasons; (ii) lack of analytical capacity to measure the plasma levels of the affected drug; (iii) difficulty in identification of the phytochemical responsible for the interaction; (iv) nonexistence of adequate genetic information especially for high-risk drugs, such as clopidogrel, warfarin, codeine, tamoxifen or terbinafine; (v) lack of standardized HDIspecific causality assessment tool; and (vi) lack of motivation of clinicians to publish HDI case reports. Critical assessment of the causality of ADRs using the recommended scoring systems reported in this study will strengthen the applicability of HDI data in clinical practice. In addition, mechanistic investigations in healthy subjects and in vitro liver models as a follow-up study on herbs recorded to elicit clinically significant HDI in patients. Thus, we recommend a bench-to-bed-side approach to understand the causal relationship of HDI linked ADRs and the potential mechanism of observed interactions. This approach will inform drug regulatory agencies and pharmaceutical companies about the need to update information in package inserts of medicines to avoid untoward adverse events, based on available data. In conclusion, causality assessment and subsequent mechanistic studies of herbs with clinically relevant HDI must be publicized to alert both clinicians and patients about the need to avoid co-usage of certain herbal medicines with specific prescribed medications.
